Business Context and Reporting Period
Company: MEDICINOVA, INC.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 2010
Business Stage: Development-stage biopharmaceutical company focused on acquiring and developing small molecule therapeutics.
Key Operations: The company has no commercial products. Its primary activities involve clinical development of prioritized candidates MN-221 (asthma/COPD) and MN-166/AV411 (CNS disorders). The company acquired Avigen, Inc. in December 2009 to combine ibudilast development programs.
Key Financial Metrics
| Metric | Six Months Ended June 30, 2010 | Six Months Ended June 30, 2009 |
|---|---|---|
| Revenues | $0 | $0 |
| Net Loss | $(9,495,310) | $(9,658,227) |
| Net Loss Per Share (Basic & Diluted) | $(0.77) | $(0.80) |
| Operating Expenses | $9,388,210 | $10,209,794 |
| Research & Development | $5,253,974 | $5,846,717 |
| General & Administrative | $4,134,236 | $4,363,077 |
| Cash and Cash Equivalents (End of Period) | $25,357,050 | $28,657,327 |
| Total Current Assets | $38,494,838 | $46,923,224 |
| Total Liabilities | $49,339,347 | $54,313,433 |
| Stockholders' Equity | $34,291,395 | $40,013,474 |
Debt and Liquidity:
- Long-Term Debt: Entered a $15.0 million loan agreement with Oxford Finance Corporation on May 10, 2010 (12.87% stated rate, 18.14% effective rate).
- Convertible Notes: $27.6 million outstanding related to the Avigen acquisition.
- ARS Loan: $2.0 million outstanding at June 30, 2010 (repaid in July 2010).
- Liquidity: Management believes existing cash and investment securities are sufficient to fund operations through at least June 30, 2011.
Material Changes vs. Prior Period
- Operating Expenses: Total operating expenses decreased by approximately $0.8 million compared to the prior year period. This was driven by a $0.5 million decrease in R&D (due to slowed enrollment in the MN-221 trial and reduced headcount) and a $0.3 million decrease in G&A (due to reduced legal/accounting fees post-Avigen transaction).
- Interest Expense: Increased significantly to $450,443 from $107,595 in the prior year, primarily due to the new $15 million Oxford loan and accretion on convertible notes.
- Investment Securities: Recorded a net gain of $56,539 on investment securities, compared to $140,826 in the prior year. This reflects the redemption of Auction Rate Securities (ARS) at par value, offset by impairment charges on the linked ARS Put.
- Debt Structure: Significant reduction in ARS loan payable (from $17.6 million to $2.0 million) due to redemptions of ARS, offset by the new $15.0 million Oxford term loan.
Guidance, Outlook, and Risks
Outlook and Management Commentary:
- The company expects to continue incurring significant net losses for the foreseeable future as it advances clinical trials.
- Primary focus remains on MN-221 (asthma/COPD) and MN-166/AV411 (CNS disorders). The MN-221 Phase II trial experienced slower-than-expected enrollment, though a protocol amendment was approved to facilitate recruitment.
- Management plans to limit development of non-prioritized candidates to maintain license rights while seeking strategic collaborations.
- Future capital requirements will depend on clinical trial progress, regulatory approvals, and the ability to secure partnerships.
Risks and Contingencies:
- Capital Needs: The company requires additional funding to sustain operations beyond mid-2011. Failure to secure capital could force delays or termination of programs.
- Debt Covenants: The Oxford loan agreement contains restrictive covenants, including a requirement to secure $15 million in collaboration proceeds or achieve positive Phase IIB data for MN-221 by March 31, 2011.
- Legal Proceedings: A lawsuit by The Pennsylvania Avenue Funds regarding the Avigen merger was settled for $140,000, paid by Avigen's insurance carrier in July 2010.
- Investment Risk: Valuation of ARS and ARS Put relies on management estimates and discounted cash flow models due to illiquid markets.
Key Facts for Investor Verification
- Cash Runway: Verify if the company has secured additional financing or partnerships to extend liquidity beyond the projected June 30, 2011 date.
- Debt Covenant Compliance: Monitor progress toward the March 31, 2011 milestone (securing $15M collaboration or positive MN-221 data) to avoid default on the Oxford loan.
- Clinical Enrollment: Track enrollment rates for the MN-221 Phase II trial following the protocol amendment to assess development timelines.
- ARS Liquidation: Confirm the final settlement of the ARS Put and the full repayment of the ARS loan, which were completed in July 2010.
- Strategic Partnerships: Evaluate the status of discussions for strategic collaborations on MN-166/AV411, as the company intends to limit independent development of this asset.